Us Bancorp \De\ Vertex Pharmaceuticals Inc Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Us Bancorp \De\ holds 30,343 shares of VRTX stock, worth $14.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

30,343

Previous 26,579 14.16%

Holding current value

$14.6 Million

Previous $12.4 Million 1.15%

% of portfolio

0.02%

Previous 0.02%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	BUY	$396.64 - $516.74 $1.49 Million - $1.95 Million	3,764 Added 14.16%	30,343 $12.2 Million
Q3 2024 Oct 28, 2024	BUY	$460.0 - $505.78 $1.05 Million - $1.15 Million	2,273 Added 9.35%	26,579 $12.4 Million
Q2 2024 Aug 06, 2024	BUY	$392.81 - $485.53 $1.12 Million - $1.39 Million	2,856 Added 13.31%	24,306 $11.4 Million
Q1 2024 May 07, 2024	BUY	$407.69 - $446.08 $932,794 - $1.02 Million	2,288 Added 11.94%	21,450 $8.97 Million
Q4 2023 Feb 09, 2024	BUY	$343.0 - $410.68 $2.08 Million - $2.49 Million	6,065 Added 46.31%	19,162 $7.8 Million
Q3 2023 Nov 03, 2023	BUY	$338.18 - $362.46 $467,702 - $501,282	1,383 Added 11.81%	13,097 $4.55 Million
Q2 2023 Aug 09, 2023	SELL	$314.42 - $351.91 $287,694 - $321,997	-915 Reduced 7.25%	11,714 $4.12 Million
Q1 2023 May 09, 2023	BUY	$283.23 - $323.1 $51,831 - $59,127	183 Added 1.47%	12,629 $3.98 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $207,461 - $233,394	-726 Reduced 5.51%	12,446 $3.59 Million
Q3 2022 Oct 27, 2022	BUY	$273.83 - $305.53 $158,273 - $176,596	578 Added 4.59%	13,172 $3.81 Million
Q2 2022 Aug 01, 2022	SELL	$234.96 - $292.55 $730,020 - $908,952	-3,107 Reduced 19.79%	12,594 $3.55 Million
Q1 2022 May 11, 2022	BUY	$221.42 - $260.97 $334,787 - $394,586	1,512 Added 10.66%	15,701 $4.1 Million
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $335,433 - $423,437	1,895 Added 15.41%	14,189 $3.12 Million
Q3 2021 Nov 10, 2021	SELL	$181.39 - $202.99 $85,978 - $96,217	-474 Reduced 3.71%	12,294 $2.23 Million
Q2 2021 Aug 05, 2021	SELL	$187.49 - $221.1 $638,965 - $753,508	-3,408 Reduced 21.07%	12,768 $2.58 Million
Q1 2021 Apr 28, 2021	BUY	$207.02 - $241.31 $428,117 - $499,029	2,068 Added 14.66%	16,176 $3.48 Million
Q4 2020 Feb 04, 2021	BUY	$207.01 - $276.09 $190,863 - $254,554	922 Added 6.99%	14,108 $3.33 Million
Q3 2020 Nov 10, 2020	BUY	$255.65 - $303.1 $248,491 - $294,613	972 Added 7.96%	13,186 $3.59 Million
Q2 2020 Aug 07, 2020	SELL	$225.48 - $295.8 $73,957 - $97,022	-328 Reduced 2.62%	12,214 $3.55 Million
Q1 2020 May 13, 2020	BUY	$199.77 - $247.81 $409,928 - $508,506	2,052 Added 19.56%	12,542 $2.98 Million
Q4 2019 Feb 04, 2020	BUY	$166.71 - $223.91 $79,520 - $106,805	477 Added 4.76%	10,490 $2.3 Million
Q3 2019 Nov 08, 2019	BUY	$166.23 - $187.09 $117,524 - $132,272	707 Added 7.6%	10,013 $1.7 Million
Q2 2019 Aug 13, 2019	BUY	$164.61 - $190.37 $52,510 - $60,728	319 Added 3.55%	9,306 $1.71 Million
Q1 2019 May 08, 2019	BUY	$163.73 - $194.7 $112,155 - $133,369	685 Added 8.25%	8,987 $1.65 Million
Q4 2018 Feb 13, 2019	BUY	$151.91 - $192.21 $159,657 - $202,012	1,051 Added 14.49%	8,302 $1.38 Million
Q3 2018 Nov 01, 2018	SELL	$167.73 - $192.74 $19,792 - $22,743	-118 Reduced 1.6%	7,251 $1.4 Million
Q2 2018 Aug 08, 2018	SELL	$145.72 - $169.96 $191,621 - $223,497	-1,315 Reduced 15.14%	7,369 $1.25 Million
Q1 2018 May 08, 2018	BUY	$151.6 - $177.13 $253,020 - $295,629	1,669 Added 23.79%	8,684 $1.42 Million
Q4 2017 Feb 02, 2018	SELL	$137.28 - $155.55 $24,984 - $28,310	-182 Reduced 2.53%	7,015 $1.05 Million
Q3 2017 Nov 13, 2017	BUY	$148.13 - $162.24 $1.07 Million - $1.17 Million	7,197	7,197 $1.09 Million

Others Institutions Holding VRTX

# of Institutions

1,757

Shares Held

228M

Call Options Held

1.63M

Put Options Held

1.47M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $123B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account